👋 New here? A quick tour of the page
📂
Sector tabs
Filter the analysis to a single sector, or stay on the first tab for the full market scan.
📈
Stock cards
Stocks ranked by positive mentions × average sentiment. Open "Why is it moving?" on any card to read the exact headlines behind the score — each one links to its original article.
🔍
Search a stock
Use the sidebar search to look up any tracked ticker or company name and see its bullish and bearish headlines side by side.
📡
Refresh & custom feeds
Hit Refresh Analysis to re-scan the latest news, or add your own RSS feed in the sidebar to include it in the scan.
Biotech picks
Ranked by positive mention count × average VADER sentiment score.
ABBV
0.544
$288.84
▼
2.05%
18 mentions
Why is ABBV moving?
▲ Why it may be rising
- Yahoo Finance AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?
- Nasdaq AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now? Key PointsAbbVie's Qulipta could be racing toward another label…
- Nasdaq Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade Key PointsAbbVie has increased its dividend for 53…
▼ Why it may be falling
- Yahoo Finance Stock Market Today: Dow Cuts Sharp Losses As Some Techs Rally; AbbVie Breaks Out (Live Coverage) The Dow Jones index drops 500 points Wednesday as Treasury yiel…
- Nasdaq How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? Key PointsAmgen, Pfizer, J&J, AbbVie, and Bristol Myers Squi…
- Nasdaq AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? Key PointsAbbVie is aggressively diversifying its pipeline to mitigate the revenue impa…
MRNA
0.504
$220.83
▼
0.40%
17 mentions
Why is MRNA moving?
▲ Why it may be rising
- Fortune Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug CI is pairing top AI and bi…
- MarketWatch Citi tells investors it’s time to sell Moderna after 600%-plus stock gains Revenue and profit forecasts fail to justify the hype baked into Moderna’s share pric…
- investorshub.advfn.com Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility Shares of Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) declined on Wednesd…
▼ Why it may be falling
- trefis.com Was Moderna Stock's Cancer Vaccine Run Visible In Advance? Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 t…
- Yahoo Finance Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell. Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vacci…
- thestreet.com Citi delivers major verdict after Moderna’s remarkable 703% run Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.
AMGN
0.632
$465.45
▼
0.12%
11 mentions
Why is AMGN moving?
▲ Why it may be rising
- Yahoo Finance Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
- Nasdaq 2 Healthcare Stocks That Just Delivered Great News for Investors Key PointsVertex Pharmaceuticals and Amgen recently posted strong clinical trial results for pr…
- Nasdaq Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Key PointsAmgen offers a diversified portfolio of established therapies across on…
▼ Why it may be falling
- Nasdaq How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? Key PointsAmgen, Pfizer, J&J, AbbVie, and Bristol Myers Squi…
- trefis.com Is Amgen Stock Increasing Your Market Risk? Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair th…
- CNBC Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer A drug from Amgen could give patients with an aggressive form of lung ca…
GILD
0.597
$170.33
▼
0.21%
8 mentions
Why is GILD moving?
▲ Why it may be rising
- Yahoo Finance Why Morgan Stanley likes Gilead's HIV prevention play
- Yahoo Finance Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive? Gilead Sciences, Inc. (NASDAQ:GILD) has had a considerably better year than the broa…
- MarketWatch Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets Shares of AbbVie, Eli Lilly and Gilead Sciences closed near recor…
VRTX
0.712
$553.15
▼
1.03%
6 mentions
Why is VRTX moving?
▲ Why it may be rising
- Nasdaq 2 Healthcare Stocks That Just Delivered Great News for Investors Key PointsVertex Pharmaceuticals and Amgen recently posted strong clinical trial results for pr…
- Nasdaq Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Key PointsAmgen offers a diversified portfolio of established therapies across on…
- Yahoo Finance Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s Why Andrew Hill Investment Advisors recently released its third-quarter 2026 invest…
REGN
0.456
$961.26
▲
3.60%
5 mentions
Why is REGN moving?
▲ Why it may be rising
- Nasdaq Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? Key PointsRegeneron's stock has underperformed the market this year, but it got a boost last time…
- Nasdaq Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies (RTTNews) - On Thursday, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced the expans…
- Nasdaq Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share Key PointsRegeneron’s revenue is growing at a good clip despite declining…
ALNY
0.664
$158.0
▼
4.24%
3 mentions
Why is ALNY moving?
▲ Why it may be rising
- Nasdaq Interesting ALNY Put And Call Options For September 2027 Investors in Alnylam Pharmaceuticals Inc (Symbol: ALNY) saw new options become available today, for the…
- Yahoo Finance Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biotechnology company built on R…
- Nasdaq Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? Key PointsAlnylam's stock has plunged more than 40% this year, but the c…
CRSP
0.501
$49.99
▼
2.78%
3 mentions
Why is CRSP moving?
▲ Why it may be rising
- Nasdaq 3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 Key PointsEven if it’s not being officially reported yet, its drug Casgevy is accrui…
- Nasdaq CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? Key PointsCRISPR Therapeutics has two important data read…
- Nasdaq Where Will CRISPR Therapeutics Stock Be in 2030? Key PointsCRISPR Therapeutics has an approved product on the market that could gain significant commercial trac…
ILMN
0.838
$226.58
▼
3.99%
2 mentions
Why is ILMN moving?
▲ Why it may be rising
- Business Insider Battleship North Carolina Memorial to Celebrate 65th Berth-Day with a Weekend of Special Community Events <link type="text/css" rel="styleshee…
- Nasdaq Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off? Illumina (NASDAQ: ILMN) is building a deeper AI strategy around the biological data created by i…
▼ Why it may be falling
- Yahoo Finance Dow Jones Futures: Amazon, Intel Lead Earnings Losers After Google, ServiceNow, Fortinet Hit Nasdaq Amazon, Intel and Illumina were earnings losers overnight af…
- Yahoo Finance Dow Jones Futures Fall, Nasdaq Futures Plunge 2% On Amazon, Intel After Google, ServiceNow, Fortinet Dive Amazon, Intel and Illumina were earnings losers overni…
- Yahoo Finance Dow Jones Futures: Nasdaq Futures Plunge 2% On Amazon, Intel After Google, ServiceNow, Fortinet Dive Amazon, Intel and Illumina were earnings losers overnight a…
TMO
0.542
$682.65
▼
2.06%
2 mentions
Why is TMO moving?
RGEN
0.534
$172.95
▼
2.26%
2 mentions
Why is RGEN moving?
▲ Why it may be rising
NTLA
0.386
$11.66
▼
6.50%
2 mentions
Why is NTLA moving?
RXRX
0.357
$3.83
▼
4.96%
2 mentions
Why is RXRX moving?
INCY
0.29
$120.04
▼
0.29%
2 mentions
Why is INCY moving?
▲ Why it may be rising
▼ Why it may be falling
- Nasdaq Relative Strength Alert For Incyte Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One w…
- Nasdaq Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer (RTTNews) - Genmab A/S (GMAB) and Incyte (INCY) have entered…
- Investing.com Incyte stock price target maintained at $152 by H.C. Wainwright on cancer drug data
BIIB
0.818
$249.01
▼
1.82%
1 mention
Why is BIIB moving?
▲ Why it may be rising
CRL
0.807
$338.54
▼
5.81%
1 mention
Why is CRL moving?
BNTX
0.477
$87.53
▼
0.73%
1 mention
Why is BNTX moving?
▲ Why it may be rising
▼ Why it may be falling
- Nasdaq BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? Key PointsBMO Capital Markets downgraded BioNTech and lowered it…
- Nasdaq Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? Key PointsBioNTech recently experienced a c…
- Nasdaq BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100? Key PointsBioNTech now has more than 25 phase 2 and pha…
BEAM
0.477
$25.87
▼
4.99%
1 mention
Why is BEAM moving?
DHR
0.44
$227.97
▼
1.83%
1 mention
Why is DHR moving?
▲ Why it may be rising
IQV
0.318
$258.44
▼
3.33%
1 mention
Why is IQV moving?
⚠ Legal Disclaimer
This tool is for educational purposes only. It does not constitute financial, investment, or legal advice. The sentiment scores and stock mentions shown here are derived from automated analysis of publicly available news and should not be used as the basis for any trading or investment decision. Past sentiment signals are not indicative of future stock performance. The creators of NewsToStocks accept no liability for any financial losses or decisions made based on this tool. Always consult a licensed financial advisor before making investment decisions.
📰 Data sources Stock prices via Yahoo Finance. News headlines from Reuters, Yahoo Finance, MarketWatch, CNBC, The Wall Street Journal, TechCrunch, Fortune, Business Insider, Investing.com, Nasdaq, CNN Business, and Reddit — each headline links to its original article, with the source publication tagged alongside it.
📰 Data sources Stock prices via Yahoo Finance. News headlines from Reuters, Yahoo Finance, MarketWatch, CNBC, The Wall Street Journal, TechCrunch, Fortune, Business Insider, Investing.com, Nasdaq, CNN Business, and Reddit — each headline links to its original article, with the source publication tagged alongside it.